Mounjaro®
Starting from £179.99/mo
Start journey Learn moreDrawing up 2.5 mg of tirzepatide is not something you will need to do. Mounjaro is supplied as a pre-filled KwikPen, and each pen is factory-set to deliver the correct dose automatically — there is nothing to measure, no syringe to fill. The 2.5 mg starting dose comes ready to inject. That said, many people searching this question are trying to understand what that dose actually looks like in volume terms, or they have seen compounded tirzepatide described online and want to know whether it is the same thing. The short answer is: licensed Mounjaro pens do not require any drawing-up at all, and compounded or unlicensed tirzepatide formulations are not legally available or approved for use in the UK. This guide walks through how the licensed pen works, what the 2.5 mg dose represents clinically, and why the distinction matters for your safety. These are prescription-only medicines, and a prescriber decides whether they are suitable for you following a clinical assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro KwikPen is a pre-filled, single-strength device. At the 2.5 mg dose, Eli Lilly has engineered the pen so that pressing the button releases the precise volume corresponding to that dose automatically. You do not handle the liquid directly. There is no vial, no syringe, no calculation to run. This is worth saying plainly because a surprising number of people arrive at this question having read posts about drawing up tirzepatide into an insulin syringe, a practice associated with unlicensed compounded formulations sold online, not with the licensed medicine.
Before your first injection, it helps to read the Patient Information Leaflet that arrives with your pen; the NHS tirzepatide information page also summarises the key steps clearly. Store the pen in the fridge (2–8°C) until you are ready to use it, then let it reach room temperature for the period specified in the leaflet before injecting. For the exact storage window, always follow the leaflet, guidelines have a way of being updated and the printed leaflet shipped with your pen reflects the current approved wording.
Attach a fresh needle, remove both needle caps, dial or confirm the dose indicator, choose your injection site (abdomen, thigh or upper arm), and press and hold the button until the dose counter returns to zero. Rotate sites each week to avoid skin changes at any one spot. Dispose of the used needle immediately in a sharps container; the pen body is removed only when empty.
The 2.5 mg strength is a starter dose) its job is to let your gastrointestinal system settle into the medicine, not to deliver the treatment's full effect. Most of the nausea and early digestive discomfort that people associate with tirzepatide is dose-related and most pronounced at the beginning; starting low and titrating gradually is the standard approach precisely because it reduces that early burden.
If you want to understand the volume that 2.5 mg occupies in the pen, the conversion is explained in detail on our page on how many ml 2.5 mg of tirzepatide is, and the broader tirzepatide mg-to-ml conversion covers all licensed doses. Those figures are informational: knowing the volume does not change anything about how you use a licensed KwikPen, but it can help people who have questions about what they are injecting feel more grounded about the process.
After four weeks at 2.5 mg, most people move to 5 mg, then upwards at roughly four-weekly steps if they are tolerating each level well. The prescriber makes that call based on your progress and how you are feeling. The titration schedule is described in detail on our 2.5 mg tirzepatide overview page and the 5 mg tirzepatide page covers what the next step involves.
Here is the misconception worth naming directly: some people believe that drawing up tirzepatide into a syringe is a normal part of using it, perhaps because they have seen this described in US-based content or on social media. In the UK, licensed Mounjaro requires no such step. If you have encountered a supplier describing vials of tirzepatide that require you to measure and draw up doses yourself, that product is not licensed Mounjaro. The MHRA has issued repeated warnings about unlicensed injectable weight-loss products sold online; some have contained dangerous substitutes. Reporting a suspect seller is straightforward via the Yellow Card scheme.
The safe route is simple: a prescription from a registered prescriber, fulfilled by a pharmacy you can verify on the GPhC register. You can check any pharmacy's registration at the GPhC pharmacy register. Genuine Mounjaro pens arrive sealed, labelled with the batch number and expiry, and accompanied by a printed Patient Information Leaflet in English. If any of those elements are missing, that is a concern worth raising.
Questions about cost are reasonable too, private treatment involves real expenditure and our Mounjaro cost page explains what a legitimate prescription service includes. For a fuller picture of the medicine itself, our Mounjaro overview covers the clinical background, trial results and what to expect from treatment.
Once you are using the pen, the practical questions tend to shift, not how to draw anything up, but how to manage the early nausea, when to expect appetite changes, and what to do if you miss a dose. Those are all questions for your prescriber or the Patient Information Leaflet, not for online searches alone. Our prescribers are available seven days a week for aftercare.
If you are still in the process of deciding whether tirzepatide is right for you, or you are considering moving from one dose to the next, the appropriate step is a clinical conversation. Speak to our prescribers through a free consultation, your answers are reviewed the same day by a GPhC-registered prescriber, not by automated software, and every repeat order goes through the same clinical check before anything is dispatched.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.